Lipotec pharma units not included in Lubrizol takeover
The deal will see Berkshire Hathaway-owned Lubrizol take control of Lipotec’s cosmetics active ingredients businesses and its skin –care units Diverdrugs and Lipofoods, but not its pharma actives divisions BCN Peptides and GP Pharm.
In a press statement Lubrizol said that: “The current owners of Lipotec Group will continue their activities in the pharmaceutical and cosmetic finished goods segments.”
BCN is a contract manufacturer focused on active pharmaceutical ingredient (API) synthesis, while fellow Barcelona-based GP Pharm develops and sells injectables using its proprietary drug delivery technology in two therapeutic areas, Urology and Oncology,
